These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp. Sader HS; Jones RN Int J Antimicrob Agents; 2005 May; 25(5):380-4. PubMed ID: 15848291 [TBL] [Abstract][Full Text] [Related]
23. Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa. Dupont P; Hocquet D; Jeannot K; Chavanet P; Plésiat P J Antimicrob Chemother; 2005 Apr; 55(4):518-22. PubMed ID: 15722391 [TBL] [Abstract][Full Text] [Related]
24. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. Hocquet D; Muller A; Blanc K; Plésiat P; Talon D; Monnet DL; Bertrand X Antimicrob Agents Chemother; 2008 Mar; 52(3):1173-5. PubMed ID: 18180356 [TBL] [Abstract][Full Text] [Related]
25. The influence of postantibiotic effects and postantibiotic effects of sub-inhibitory concentrations of quinolones and aminoglycosides on phospholipase C of Pseudomonas aeruginosa. Hybenová D; Majtán V Pharmazie; 1997 Feb; 52(2):157-9. PubMed ID: 9122276 [TBL] [Abstract][Full Text] [Related]
26. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 6: exploration of aromatic substituents. Yoshida K; Nakayama K; Yokomizo Y; Ohtsuka M; Takemura M; Hoshino K; Kanda H; Namba K; Nitanai H; Zhang JZ; Lee VJ; Watkins WJ Bioorg Med Chem; 2006 Dec; 14(24):8506-18. PubMed ID: 16979895 [TBL] [Abstract][Full Text] [Related]
27. Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype. Wolter DJ; Black JA; Lister PD; Hanson ND J Antimicrob Chemother; 2009 Aug; 64(2):294-300. PubMed ID: 19468029 [TBL] [Abstract][Full Text] [Related]
28. [In vitro effects of aztreonam against Pseudomonas aeruginosa]. Marone P; Concia E; Perversi L; Monzillo V; Cruciani M G Ital Chemioter; 1985; 32(2):411-4. PubMed ID: 3938743 [No Abstract] [Full Text] [Related]
29. Molecular characterization of the outer membrane of Pseudomonas aeruginosa. López CA; Zgurskaya H; Gnanakaran S Biochim Biophys Acta Biomembr; 2020 Mar; 1862(3):183151. PubMed ID: 31846648 [TBL] [Abstract][Full Text] [Related]
30. Mutant Alleles of lptD Increase the Permeability of Pseudomonas aeruginosa and Define Determinants of Intrinsic Resistance to Antibiotics. Balibar CJ; Grabowicz M Antimicrob Agents Chemother; 2016 Feb; 60(2):845-54. PubMed ID: 26596941 [TBL] [Abstract][Full Text] [Related]
31. Molecular Interactions of Lipopolysaccharide with an Outer Membrane Protein from Pseudomonas aeruginosa Probed by Solution NMR. Kucharska I; Liang B; Ursini N; Tamm LK Biochemistry; 2016 Sep; 55(36):5061-72. PubMed ID: 27532487 [TBL] [Abstract][Full Text] [Related]
32. Antibiotic uptake pathways across the outer membrane of Pseudomonas aeruginosa. Moore RA; Woodruff WA; Hancock RE Antibiot Chemother (1971); 1987; 39():172-81. PubMed ID: 2823689 [No Abstract] [Full Text] [Related]
33. Outer membrane proteins and elastase of Pseudomonas aeruginosa after the postantibiotic effect induced by amikacin. Hostacká A; Karelová E Chemotherapy; 1997; 43(2):118-22. PubMed ID: 9084920 [TBL] [Abstract][Full Text] [Related]
34. Crystal structure of LptH, the periplasmic component of the lipopolysaccharide transport machinery from Pseudomonas aeruginosa. Bollati M; Villa R; Gourlay LJ; Benedet M; Dehò G; Polissi A; Barbiroli A; Martorana AM; Sperandeo P; Bolognesi M; Nardini M FEBS J; 2015 May; 282(10):1980-97. PubMed ID: 25735820 [TBL] [Abstract][Full Text] [Related]
35. Use of steroids to monitor alterations in the outer membrane of Pseudomonas aeruginosa. Plesiat P; Aires JR; Godard C; Köhler T J Bacteriol; 1997 Nov; 179(22):7004-10. PubMed ID: 9371446 [TBL] [Abstract][Full Text] [Related]
36. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Zhang L; Dhillon P; Yan H; Farmer S; Hancock RE Antimicrob Agents Chemother; 2000 Dec; 44(12):3317-21. PubMed ID: 11083634 [TBL] [Abstract][Full Text] [Related]
37. The interaction of a recombinant cecropin/melittin hybrid peptide with the outer membrane of Pseudomonas aeruginosa. Piers KL; Hancock RE Mol Microbiol; 1994 Jun; 12(6):951-8. PubMed ID: 7934902 [TBL] [Abstract][Full Text] [Related]
38. The Pseudomonas aeruginosa outer membrane permeability barrier and how to overcome it. Hancock RE Antibiot Chemother (1971); 1985; 36():95-102. PubMed ID: 2988427 [TBL] [Abstract][Full Text] [Related]
39. Association of resistance to trimethoprim/sulphamethoxazole, chloramphenicol and quinolones with changes in major outer membrane proteins and lipopolysaccharide in Burkholderia cepacia. Rajyaguru JM; Muszynski MJ J Antimicrob Chemother; 1997 Dec; 40(6):803-9. PubMed ID: 9462431 [TBL] [Abstract][Full Text] [Related]
40. Deficient Pseudomonas aeruginosa in MlaA/VacJ outer membrane lipoprotein shows decrease in rhamnolipids secretion, motility, and biofilm formation, and increase in fluoroquinolones susceptibility and innate immune response. Kaur M; Buyck JM; Goormaghtigh F; Decout JL; Mozaheb N; Mingeot-Leclercq MP Res Microbiol; 2023; 174(8):104132. PubMed ID: 37660742 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]